In this study, FCT-treated groups (FCT-M and -H) showed reduced prostate weight, DHT levels in both serum and prostate tissue, and reduced 5AR and AR expression levels in a testosterone-propionate induced BPH animal model. The gene discussed is AR; the disease is benign prostatic hyperplasia.